Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-3 (of 3 Records) |
Query Trace: Thorley M[original query] |
---|
Concurrent outbreaks of circulating vaccine-derived poliovirus types 1 and 2 affecting the Republic of the Philippines and Malaysia, 2019-2021.
Snider CJ , Boualam L , Tallis G , Takashima Y , Abeyasinghe R , Lo YR , Grabovac V , Avagyan T , Aslam SK , Eltayeb AO , Aung KD , Wang X , Shrestha A , Ante-Orozco C , Silva MWT , Lapastora-Sucaldito N , Apostol LNG , Jikal MBH , Miraj W , Lodhi F , Kim HJ , Rusli N , Thorley BR , Kaye MB , Nishimura Y , Arita M , Sani JAM , Rundi C , Feldon K . Vaccine 2022 41 Suppl 1 A58-A69 Concurrent outbreaks of circulating vaccine-derived poliovirus serotypes 1 and 2 (cVDPV1, cVDPV2) were confirmed in the Republic of the Philippines in September 2019 and were subsequently confirmed in Malaysia by early 2020. There is continuous population subgroup movement in specific geographies between the two countries. Outbreak response efforts focused on sequential supplemental immunization activities with monovalent Sabin strain oral poliovirus vaccine type 2 (mOPV2) and bivalent oral poliovirus vaccines (bOPV, containing Sabin strain types 1 and 3) as well as activities to enhance poliovirus surveillance sensitivity to detect virus circulation. A total of six cVDPV1 cases, 13 cVDPV2 cases, and one immunodeficiency-associated vaccine-derived poliovirus type 2 case were detected, and there were 35 cVDPV1 and 31 cVDPV2 isolates from environmental surveillance sewage collection sites. No further cVDPV1 or cVDPV2 have been detected in either country since March 2020. Response efforts in both countries encountered challenges, particularly those caused by the global COVID-19 pandemic. Important lessons were identified and could be useful for other countries that experience outbreaks of concurrent cVDPV serotypes. |
Notes from the field: Circulating vaccine-derived poliovirus type 1 and outbreak response - Papua New Guinea, 2018
Bauri M , Wilkinson AL , Ropa B , Feldon K , Snider CJ , Anand A , Tallis G , Boualam L , Grabovac V , Avagyan T , Reza MS , Mekonnen D , Zhang Z , Thorley BR , Shimizu H , Apostol LNG , Takashima Y . MMWR Morb Mortal Wkly Rep 2019 68 (5) 119-120 The last poliomyelitis cases reported in Papua New Guinea occurred in 1996. Papua New Guinea is one of 37 countries (or areas) of the World Health Organization Western Pacific Region that were certified free of indigenous wild poliovirus in 2000. On June 22, 2018, the National Department of Health confirmed an outbreak of poliomyelitis caused by circulating vaccine-derived poliovirus type 1 (cVDPV1) following isolation of genetically linked virus from a patient with paralysis and nonhousehold community contacts. The index patient was a boy aged 6 years from Lae, Morobe Province, with onset of paralysis on April 25 and history of having received 2 doses of Sabin oral poliovirus vaccine (OPV).* Genetic characterization of the isolate identified 14 nucleotide differences from the Sabin 1 strain in the VP1 coding region, suggesting circulation for >1 year. As of February 4, 2019, a total of 26 confirmed cases had been identified in nine of 22 provinces, including 19 in children aged <5 years, six in patients aged 5–14 years, and one in a patient aged 17 years. The most recent case onset was October 18, 2018 (Figure). Eighteen (69%) cases were linked to areas with large transient populations, including those near mines or plantations. |
Timing of hepatitis B vaccination and impact of non-simultaneous vaccination with DTP vaccine following introduction of a hepatitis B birth dose in the Philippines
Wallace AS , Sobel H , Ryman TK , Mantaring Iii JB , Silvestre M , Thorley M , Ducusin J , Nyunt US . J Public Health Policy 2012 33 (3) 368-381 Timely administration of hepatitis B vaccine beginning at birth prevents up to 95 per cent of perinatally acquired hepatitis B virus infections in infants of infected mothers. The Philippines changed its national HepB schedule in 2007 to include a dose at birth. We evaluated vaccination schedule change by reviewing infant records at selected health facilities to measure completeness and timeliness of HepB administration and frequency of recommended, simultaneous vaccination with diphtheria-tetanus-pertussis (DTP) vaccine. Of 1431 sampled infants, 1106 (77 per cent) completed the HepB series and 10 per cent followed the national schedule. The proportion with timely vaccination declined with successive doses: HepB1 (71 per cent), HepB2 (47 per cent), and HepB3 (26 per cent). Twenty-six per cent received HepB2 simultaneously with DTP1 and 34 per cent received HepB3 simultaneously with DTP3. If HepB and DTP vaccination were given simultaneously, 10 per cent more infants could have received all HepB doses. Program implementers should monitor vaccination timeliness and increase simultaneous administration to improve vaccination coverage and decrease disease incidence. (Journal of Public Health Policy advance online publication, 7 June 2012; doi:10.1057/jphp.2012.18.) |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure